• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Ilumya territory turn-over





































































94 TMs and 3 have left. That is better than Humira, Cosentyx, Taltz etc launch. Maybe so many stick it out because they are more mature here and less flighty. It is an outstanding team from top to bottom. There is no mass exodus so stop trying to make something out of nothing. Management is taking notes on who the trouble makers are.
 




94 TMs and 3 have left. That is better than Humira, Cosentyx, Taltz etc launch. Maybe so many stick it out because they are more mature here and less flighty. It is an outstanding team from top to bottom. There is no mass exodus so stop trying to make something out of nothing. Management is taking notes on who the trouble makers are.

We have turned over more than 3. 2 in the midatlantic, 1 in the carolina's (soon to be multiple), 1 in KY, 1 in Little Rock. That is 5, and that isn't all the positions turned over that are listed. Notice there are none listed in the west, but some have left. So we are somewhere between 7-10%, which is bad considering we have been ACTUALLY MARKETING DRUG about 4 months.